Global Women’s Health Therapeutics Market Size Worth USD 78.5 Billion by 2026 – AXIOM MRC

Global Womens Health Therapeutics Market  Axiom MRC

Axiom MRC estimated global women’s health therapeutics market to grow at a CAGR of 5.90% during the forecast period 2020 to 2026

(YourDigitalWall Editorial):- Wilmington, Jan 14, 2020 ( – January 14, 2020: Axiom Market Research & Consulting added a report on global women’s health therapeutics market which includes study on various diseases conditions associated with women’s health and treatment type across various countries of key regions around the world. The global market is estimated and forecasted in terms of revenue (USD billion) generated by the women’s health therapeutics market.

More on your digital wall:

Browse report details:

The major treatment type of women’s health are hormonal treatment and non-hormonal treatment. Non-hormonal treatment consists of targeted drugs, antibiotics, bisphosphonates, calcitonin, non-steroidal anti-inflammatory drugs etc. The non-hormonal treatment was recorded at largest market share of over 50% in 2019. Increasing preference for the non-hormonal treatment, and new product development are the key factors for the segment growth. Also, risk of breast cancer associated with the hormonal treatment has enhanced the demand for non-hormonal treatment products.

Hormonal treatment type is accessible as estrogen therapy, progestin therapy, combination therapy, thyroid replacement therapy, parathyroid hormone therapy, calcitonin etc. Hormone replacement therapy refers to a type of treatment which involves the management of low levels of hormones, resulting from lack of secretion in the human body. It is suitable for use as a contraceptives, for elderly patients suffering from hypogonadism, women in menopausal transition and patients with deficiency of growth hormone.

Download sample report:

Various diseases concerned with human women’s health including breast cancer, cervical cancer, ovarian cancer, hypothyroidism, post-menopausal syndrome, osteoporosis, contraceptive, uterine fibroid, and urinary tract infection etc. are studied in this report. Diseases such as PCOS, stress are also taken into consideration. The cancer segment is believed to account for the major chunk of the market owing to the higher and continuously increasing prevalence of breast cancer across the world. As per estimates provided by the Breast Cancer Organization in 2018, it is estimated that over 2,66,120 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer.

Geographically, the global women’s health therapeutics industry is studied for North America, Europe, Asia Pacific and Rest of the World.  The North America is anticipated to remain the largest market for women’s health therapeutics owing to investments made in cutting-edge drug research resulting in new, increasing emphasis on cancer care, and presence of major players in the region. Whereas, Asia pacific market is projected to developed with highest CAGR over forecast period. Emerging markets such as China and India with their populations in billions have become a potent source of revenue.

The major players involved in this market are Eli Lilly  and Company (US), Novartis AG (Switzerland), Pfizer, Inc.(US), Merck & Co., Inc.(US), Novo Nordisk A/S (Denmark), Amgen Inc (US), AstraZeneca (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi, (France), Allergan Plc (Ireland),  GlaxoSmithKline plc (UK) and Lupin Pharmaceuticals, Inc. (India) among others.

Other Report from Axiom MRC:

 Global Cosmetic Gynecology Market Repor Forecasts Upto 2026


Media Contact

Ganesh Sai


3 Germay Dr. Ste 4-4666, Wilmington , DE 19804

Axiom MRC
3 Germay Dr. Ste 4-4666, Wilmington , DE 19804


This Press Release was originally published by IssueWire. Read the original article here.

More on your digital wall: